Baxter International, Inc. Baxter Healthcare Corp. Baxter Diagnostics, Inc. v. Roger J. Morris, Dr.
This text of 11 F.3d 90 (Baxter International, Inc. Baxter Healthcare Corp. Baxter Diagnostics, Inc. v. Roger J. Morris, Dr.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
Baxter International, Inc., Baxter Healthcare Corp., and Baxter Diagnostics, Inc. (collectively “Baxter”) appeal from the district court’s denial of a Federal Rule of Civil Procedure 60(b) motion for relief from judgment based on newly discovered evidence. The district court 1 held that Baxter did not exercise sufficient diligence in discovery before trial to warrant relief from the judgment and that Baxter failed to demonstrate that the evidence would probably result in a different verdict if it were presented at a new trial. We affirm.
I. BACKGROUND
The facts of the underlying action are thoroughly discussed in our previous opinion. Baxter Int’l, Inc. v. Morris, 976 F.2d 1189 (8th Cir.1992). We therefore only summarize the relevant background. Baxter brought suit against Dr. Roger J. Morris, a research scientist and former Baxter employee, to enforce the terms of a noncompetition agreement and to enjoin him from disclosing its proprietary information to Baxter’s main competitor and Morris’ new employer, bioM-erieux Yitek, Inc. (“Vitek”). Baxter claimed that Morris would inevitably disclose its trade secrets to Vitek through his work. The district court enjoined Morris from disclosing certain items of confidential information to Vitek for one year, but refused to enjoin Morris from beginning employment with Vitek. Baxter appealed and we affirmed.
While Baxter’s previous appeal was pending, Baxter filed a motion for relief from judgment under Rule 60(b)(2). Baxter claimed to have discovered after trial that Morris — in conjunction with Frank J. Swen-son, another former Baxter employee — had used Baxter’s proprietary information to prepare a “Confidential Business Plan” in 1988 for a start-up company named Microphoton-ies Corp. (“MPX”). The MPX Plan was allegedly discovered during Baxter’s deposition of Swenson in a pending California action. Baxter Diagnostics, Inc. v. AVL Scientific Corp., 798 F.Supp. 612 (C.D.Cal.1992). Baxter attached a copy of the MPX Plan to the *92 Rule 60(b) motion. 2 Baxter contends that this new information easts doubt on Morris’ veracity at his deposition and at trial. According to Baxter, this evidence — which Baxter could not find through diligent discovery before trial — probably would have changed the outcome at trial because it demonstrates that Morris could not be trusted to keep Baxter’s proprietary information secret. The district court disagreed and denied Baxter’s Rule 60(b) motion without an evidentia-ry hearing.
II. DISCUSSION
Rule 60(b) “provides for extraordinary relief which may be granted only upon an adequate showing of exceptional circumstances.” United States v. Young, 806 F.2d 805, 806 (8th Cir.1986) (per curiam), cert. denied, 484 U.S. 836, 108 S.Ct. 117, 98 L.Ed.2d 76 (1987). To prevail on its Rule 60(b)(2) motion, Baxter needed to establish: “(1) the evidence was discovered after trial; (2) [Baxter] exercised due diligence to discover the evidence before the end of the trial; (3) the evidence is material and not merely cumulative or impeaching; and (4) a new trial at which the evidence was introduced would probably produce a different result.” Peterson v. General Motors Corp., 904 F.2d 436, 440 (8th Cir.1990). Motions under Rule 60(b) are within the discretion of the district court and we reverse the district court’s denial of a Rule 60(b) motion only when the court clearly abused its discretion. Id.; Rosebud Sioux Tribe v. A & P Steel, Inc., 733 F.2d 509, 515 (8th Cir.) (motions under Rule 60(b) are viewed with disfavor), cert. denied, 469 U.S. 1072, 105 S.Ct. 565, 83 L.Ed.2d 506 (1984).
Baxter asserts that Morris gave misleading testimony at his deposition to keep Baxter from discovering the MPX Plan and that “[f]or the District Court now to suggest that Baxter erred in accepting the testimony of a sworn witness and for failing to assume guile and intrigue on behalf of Dr. Morris is preposterous.” Appellants’ Brief at 11. The only portion of Morris’ deposition that Baxter cites to support its contention is an exchange regarding Morris’ possible employment opportunities at AVL Scientific Corp. (“AVL”). 3 Baxter alleges that this exchange is a veiled reference to MPX. Morris explained by affidavit in response to Baxter’s allegations that MPX was to be an independent company *93 which would license patent technology from AVL and that he did not consider starting an independent company to be an employment opportunity with AVL. Affidavit of Dr. Roger Morris, Joint App. at 49. Accordingly, he did not offer information about MPX in response to Baxter’s questions.
The district court rejected Baxter’s argument in favor of Morris’ explanation. The court also pointed out that Baxter had other avenues to discover the MPX Plan. We agree. Baxter’s subsequent discovery of the MPX Plan without Morris’ aid demonstrates that other avenues were available. The MPX Plan does not prove that any of Morris’ deposition responses were untruthful, though they may have been somewhat evasive. Our review of the deposition transcript suggests that Baxter did not ask the right questions to elicit answers regarding MPX from Morris. Baxter’s assertion that Morris’ silence was misleading or that Morris should have volunteered possibly damaging information is unavailing. Moreover, there is no indication from Baxter’s questions at the deposition, or at trial, that Baxter accorded Morris a presumption of credibility because he was under oath. We find no error in the district court’s conclusion that Baxter’s discovery lacked the due diligence required for a successful Rule 60(b) motion.
Baxter has also failed to demonstrate that the MPX Plan would likely have produced a different result if presented at trial. Baxter’s citation to Rosebud Sioux Tribe is inap-posite. In that case, a principal witness for the prevailing party directly contradicted his deposition testimony — which was read into the record at trial — at a subsequent grand jury hearing and testified that he had given false testimony during the deposition. Rosebud Sioux Tribe, 733 F.2d at 514-15. The court found that “[a]t the very least, his inconsistent stories demonstrate that he is a liar” and that the questionable deposition testimony was significant enough to have affected the jury’s verdict. Id. at 517.
The MPX Plan, however, does not directly contradict any testimony at trial. It is offered only to impeach Morris’ character and to suggest that Morris was undeserving of the district court’s trust that he could follow the court’s order.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
11 F.3d 90, 27 Fed. R. Serv. 3d 590, 1993 U.S. App. LEXIS 30949, 1993 WL 485215, Counsel Stack Legal Research, https://law.counselstack.com/opinion/baxter-international-inc-baxter-healthcare-corp-baxter-diagnostics-inc-ca8-1993.